ImmunityBio, Inc. (IBRX): who owns it and who trades it
As of Nov 16, 2026, IBRX insiders reported 16 open-market sales worth $9.5M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Barry J. Simon (Director), with $4.4M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling ImmunityBio
From the latest filingsOverall: more buying than selling. Congress mostly bought. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns IBRX
402 funds and institutions reported IBRX shares worth $1.8B at the end of Q2 2026, about 20% of the company. The largest holder is BlackRock, Inc. with 3.3%.
Funds and institutions (13F) 20%Everyone else 80%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 34.08M | 3.25% | $298M | +29% |
| State Street Corp | 21.40M | 2.04% | $187M | +21% |
| Vanguard Portfolio Management LLC | 17.86M | 1.71% | $156M | +9% |
| Vanguard Capital Management LLC | 15.69M | 1.50% | $137M | +4% |
| D. E. Shaw & Co., Inc. | 11.55M | 1.10% | $101M | -8% |
| Two Sigma Investments, LP | 11.10M | 1.06% | $97.2M | +153% |
| Geode Capital Management, LLC | 9.85M | 0.94% | $86.2M | +23% |
| Millennium Management LLC | 5.58M | 0.53% | $48.9M | +293% |
| Northern Trust Corp | 3.57M | 0.34% | $31.2M | +42% |
| Morgan Stanley | 3.43M | 0.33% | $30.1M | -15% |
| Goldman Sachs Group Inc | 3.23M | 0.31% | $28.3M | -0% |
| UBS Group AG | 3.20M | 0.31% | $28M | +9% |
| Charles Schwab Investment Management Inc | 2.89M | 0.28% | $25.3M | +17% |
| Sixth Street Partners Management Company, L.P. | 2.89M | 0.28% | $25.3M | – |
| Woodline Partners LP | 2.50M | 0.24% | $21.9M | -27% |
| SEB Asset Management AB | 2.45M | 0.23% | $21.4M | No change |
| Vanguard Fiduciary Trust Co | 2.41M | 0.23% | $21.1M | +14% |
| Bank of America Corp | 2.18M | 0.21% | $19.1M | -11% |
| Voloridge Investment Management, LLC | 1.72M | 0.16% | $15.1M | -41% |
| Federated Hermes, Inc. | 1.71M | 0.16% | $15M | +24% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, IBRX insiders reported $0 of open-market purchases and $9.5M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Barry J. Simon | Director | Sale plan | 25,000 | $10.75 | $269K | Form 4 |
| Oct 2, 2026 | Cheryl Cohen | Director | Sale plan | 81,056 | $10.50 | $851K | Form 4 |
| Jul 2, 2026 | Cheryl Cohen | Director | Sale plan | 131,210 | $9.50 | $1.2M | Form 4 |
| Jul 1, 2026 | Christobel Selecky | Director | Sale plan | 159,478 | $9.02 | $1.4M | Form 4 |
| Jun 30, 2026 | Christobel Selecky | Director | Sale plan | 1,000 | $9.00 | $9K | Form 4 |
| Jun 29, 2026 | Christobel Selecky | Director | Sale plan | 95,722 | $9.01 | $862K | Form 4 |
| Jun 24, 2026 | Barry J. Simon | Director | Sale plan | 25,000 | $7.88 | $197K | Form 4 |
| Jun 4, 2026 | Barry J. Simon | Director | Sale plan | 23,033 | $7.18 | $165K | Form 4 |
| Feb 24, 2026 | Barry J. Simon | Director | Sale plan | 75,000 | $12.01 | $901K | Form 4 |
| Feb 23, 2026 | Christobel Selecky | Director | Sale plan | 25,000 | $10.00 | $250K | Form 4 |
| Feb 23, 2026 | Barry J. Simon | Director | Sale plan | 165,000 | $10.25 | $1.7M | Form 4 |
| Feb 20, 2026 | Barry J. Simon | Director | Sale plan | 10,000 | $9.25 | $92.5K | Form 4 |
| Jan 20, 2026 | Barry J. Simon | Director | Sale plan | 75,000 | $7.88 | $591K | Form 4 |
| Jan 20, 2026 | Barry J. Simon | Director | Sale plan | 76,967 | $6.54 | $503K | Form 4 |
| Jan 20, 2026 | Christobel Selecky | Director | Sale plan | 25,000 | $7.51 | $188K | Form 4 |
| Jan 16, 2026 | Christobel Selecky | Director | Sale plan | 50,000 | $5.00 | $250K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Barry J. Simon | Director | – | $4.4M | Oct 5, 2026 |
| Christobel Selecky | Director | – | $3M | Jul 1, 2026 |
| Cheryl Cohen | Director | – | $2.1M | Oct 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
IBRX short interest
High short interest. 11.9% of IBRX shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went down 5%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 126.08M IBRX shares were sold short, 11.9% of the shares outstanding, up 2.6% from the report before. At the average daily volume of 11.70M shares, buying them all back would take about 10.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 126.08M | 11.90% | +3% | 11.70M | 10.8 |
| Oct 15, 2026 | 122.95M | 11.60% | -1% | 17.19M | 7.2 |
| Sep 30, 2026 | 124.09M | 11.71% | -1% | 13.97M | 8.9 |
| Sep 15, 2026 | 125.41M | 11.83% | -0% | 7.91M | 15.9 |
| Aug 31, 2026 | 125.64M | 11.85% | -1% | 8.51M | 14.8 |
| Aug 14, 2026 | 127.50M | 12.03% | -1% | 8.26M | 15.4 |
| Jul 31, 2026 | 129.00M | 12.17% | -4% | 8.90M | 14.5 |
| Jul 15, 2026 | 134.40M | 12.83% | +2% | 11.27M | 11.9 |
| Jun 30, 2026 | 131.83M | 12.59% | -2% | 15.22M | 8.7 |
| Jun 15, 2026 | 135.15M | 12.90% | +2% | 11.31M | 11.9 |
| May 29, 2026 | 132.14M | 12.62% | -0% | 17.30M | 7.6 |
| May 15, 2026 | 132.75M | 12.68% | -4% | 12.57M | 10.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded IBRX
Since Nov 17, 2024, 1 member of Congress reported 2 purchases and 0 sales of IBRX. The latest was a purchase by Lisa C. McClain on Sep 30, 2026, reported Oct 12, 2026.
Purchases 2Sales 0
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Oct 12, 2026 | Report |
| Sep 28, 2026 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Oct 12, 2026 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
ImmunityBio company events
ImmunityBio filed 19 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Nov 9, 2026AnnouncementShared information with investors. Filing
- Oct 14, 2026AnnouncementShared information with investors. Filing
- Aug 4, 2026ResultsReleased financial results. Filing
- Jul 30, 2026AnnouncementShared information with investors. Filing
- Jun 10, 2026VoteReported shareholder vote results. Filing
- May 18, 2026AgreementImmunityBio, Inc., a Delaware corporation, entered into an exclusive development and supply agreement with Japan BCG Laboratory, a Japanese corporation. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 9, 2026ResultsReleased financial results. Filing
- Apr 6, 2026AnnouncementShared information with investors. Filing
- Mar 31, 2026AgreementImmunityBio, Inc. entered into a Second Amendment to Revenue Interest Purchase Agreement by and among the Company, the guarantors party thereto, the purchasers party thereto and Infinity SA LLC, as collateral agent and administrative agent for the Purchasers, which amends that certain Revenue… Filing
- Feb 23, 2026ResultsReleased financial results. Filing
- Feb 18, 2026AnnouncementImmunityBio, Inc. issued a press release announcing that the Company has received authorization from the European Commission for ANKTIVA ® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, which expands global access of our product to 33 countries. Filing
- Jan 26, 2026AgreementImmunityBio, Inc. entered into a letter amendment to that certain convertible Second Amended and Restated Promissory Note, dated December 10, 2024, in an outstanding principal amount of $505.0 million, by and among the Company and Nant Capital, LLC, an entity affiliated with Dr. Patrick… Filing
- Jan 15, 2026ResultsReleased financial results. Filing
- Jan 14, 2026AnnouncementImmunityBio, Inc. issued press releases announcing that The Saudi Food and Drug Authority (SFDA) has granted accelerated approval of: • ANKTIVA ® for use in combination with immune checkpoint inhibitors for the treatment of adult patients with metastatic non-small cell lung cancer whose disease has… Filing
- Dec 29, 2025AgreementImmunityBio, Inc. entered into Amendment No. 1 to the Open Market Sale Agreement SM dated April 30, 2021, with Jefferies LLC relating to the sale and issuance of shares of its common stock, par value $0.0001 per share, from time to time through an “at the market” offering program under which the… Filing
- Dec 15, 2025LeadershipThe board of directors of ImmunityBio, Inc. appointed Bruce Wendel to the Board, effective as of December 12, 2025, with a term expiring at the Company’s 2026 annual meeting of stockholders. Filing
- Dec 12, 2025AnnouncementImmunityBio, Inc. issued a press release announcing certain regulatory updates. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
ImmunityBio financials
Famous investors that hold IBRX
2 of the 50 well-known investors we track reported holding IBRX in their latest 13F filing. The largest position is Israel Englander's, worth $36M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 3.82M | $36M | 0.0% | -32% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 717,776 | $6.8M | 0.0% | +428% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about ImmunityBio, Inc. (IBRX) stock
Who owns the most IBRX stock?
The largest reported owner of ImmunityBio, Inc. (IBRX) is BlackRock, Inc., with 3.3% of the company. In total, 402 funds and institutions reported holding IBRX at the end of Q2 2026, together about 20% of the shares. See the largest owners.
Are IBRX insiders buying or selling?
In the last 12 months, IBRX insiders reported no open-market purchases and 16 sales worth $9.5M. The latest trade was on Oct 5, 2026. See every trade.
What is the short interest in IBRX?
As of Oct 30, 2026, 126.08M IBRX shares were sold short, 11.9% of the shares outstanding, up 2.6% from the report before. At the average daily volume of 11.70M shares, buying them all back would take about 10.8 trading days (days to cover). See the history.
Have members of Congress traded IBRX?
Yes. 1 member of Congress reported 2 purchases and 0 sales of IBRX since Nov 17, 2024. The latest was reported on Oct 12, 2026. See the trades.
Which famous investors hold IBRX?
2 of the 50 well-known investors we track reported IBRX in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $36M. See all holders.
Executive pay
ImmunityBio's chief executive was paid a total of $12.7M for the year ended Dec 31, 2025, up 16% from $11M the year before. In the last 12 months, ImmunityBio's executives and directors bought no stock on the open market and sold $9.5M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.